Leukocytapheresis in patients with inflammatory bowel diseases

Małgorzata Woźniak; Ilona Kurnatowska; Ewa Małecka-Panas; Renata Talar-Wojnarowska

doi:10.5114/pg.2021.106658

eISSN: 1897-4317
ISSN: 1895-5770

Gastroenterology Review/Przegląd Gastroenterologiczny

Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

2/2021
vol. 16

Send email

Copy url:

abstract:

Review paper

Leukocytapheresis in patients with inflammatory bowel diseases

Małgorzata Woźniak

¹

,

Ilona Kurnatowska

^{2, 3}

,

Ewa Małecka-Panas

¹

,

Renata Talar-Wojnarowska

¹

Department of Digestive Tract Diseases, Medical University of Lodz, Lodz, Poland
Department of Clinical Pharmacology, 1st Chair of Internal Medicine, Medical University of Lodz, Lodz, Poland
Department of Nephrology, Norbert Barlicki University Hospital, Lodz, Poland

Gastroenterology Rev 2021; 16 (2): 99–105

DOI: https://doi.org/10.5114/pg.2021.106658

Online publish date: 2021/06/04

View full text Get citation

PlumX metrics:

Leukocytapheresis, a blood purification therapy, exerts anti-inflammatory effects by removing activated leukocytes from the peripheral blood through extracorporeal circulation. It is a potential option of treatment for patients with inflammatory bowel diseases (IBD), especially those with ulcerative colitis (UC), who do not respond to conventional therapy. Given that it has a favourable safety profile and seems to have steroid sparing effects, its position in the treatment of UC is likely to expand. However, there is inadequate evidence to draw any conclusions about the efficacy of leukocytapheresis in patients with Crohn’s disease, and it should only be used in accordance with special arrangements for consent. Considering the current level of knowledge, it is essential to conduct large, well-designed, randomized clinical trials to evaluate the effects of leukocytapheresis in the management of IBD patients.

keywords:

Leukocytapheresis in patients with inflammatory bowel diseases

Małgorzata Woźniak 1 , Ilona Kurnatowska 2, 3 , Ewa Małecka-Panas 1 , Renata Talar-Wojnarowska 1

leukocytapheresis, ulcerative colitis, Crohn’s disease

Małgorzata Woźniak

¹

,

Ilona Kurnatowska

^{2, 3}

,

Ewa Małecka-Panas

¹

,

Renata Talar-Wojnarowska

¹